Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

Current Pulmonology Reports, published by SPRINGER, stands as a vital resource in the realm of respiratory health, delivering peer-reviewed research that informs clinical practices and advances understanding within the field of pulmonology. With an E-ISSN of 2199-2428, this journal captures the latest findings and technological innovations pertinent to respiratory diseases, treatment protocols, and patient management strategies. Although currently classified as non-open access, it ensures robust dissemination of significant research contributions which are essential for professionals and scholars alike. The journal's objective is not only to foster a deeper understanding of lung health issues but also to bridge the gap between research and application, thereby impacting real-world practices. As the demand for comprehensive studies in pulmonology continues to grow, Current Pulmonology Reports seeks to maintain its position as a premier outlet for quality research, ultimately bettering outcomes in respiratory medicine.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

LUNG CANCER, published by Elsevier Ireland Ltd, is a pivotal academic journal dedicated to advancing knowledge in the fields of Cancer Research, Oncology, and Pulmonary and Respiratory Medicine. With an impressive impact factor reflected by its Q1 ranking across three key categories for 2023, this journal occupies a prestigious position within the research community, emphasizing quality and significance in published works. Since its inception in 1985, LUNG CANCER has provided a comprehensive platform for researchers and clinicians to disseminate findings and novel insights, enhancing the understanding and treatment of lung cancer. The journal stands out with Scopus rankings, placing it in the top percentile across multiple relevant fields, including a notable rank of #20 in Pulmonary and Respiratory Medicine. By fostering collaboration among scholars, the journal aims to facilitate innovative research and promote evidence-based practices that could transform patient outcomes. As such, LUNG CANCER is an essential resource for those navigating this complex area of study, from seasoned researchers to aspiring professionals.

CHEST is a premier journal published by Elsevier, focusing on the vital fields of cardiology, critical care, and pulmonary medicine. Established in 1970, this esteemed journal has continually provided authoritative research, reviews, and clinical studies, catering to a global audience of healthcare professionals, researchers, and students. With an impressive impact factor, CHEST ranks in the top quartile (Q1) across its core categories according to the latest Scopus metrics, securing its position as a leading resource within cardiology (Rank #16), pulmonary (Rank #9), and critical care (Rank #8). Published quarterly, it offers a wealth of knowledge essential for advancing understanding and improving patient outcomes in these critical areas of healthcare. Researchers and practitioners are encouraged to submit their work, contributing to the ongoing discourse that shapes innovative practices and policies in respiratory and cardiovascular health.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.